AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,365,428 | +24.0% | 358,999 | +28.0% | 0.03% | +32.0% |
| Q2 2023 | $3,521,623 | +32.9% | 280,384 | +17.4% | 0.02% | +25.0% |
| Q1 2023 | $2,649,357 | -9.2% | 238,896 | -0.1% | 0.02% | -9.1% |
| Q4 2022 | $2,919,228 | -33.3% | 239,085 | -42.9% | 0.02% | -38.9% |
| Q3 2022 | $4,374,000 | -5.2% | 418,923 | -2.5% | 0.04% | +2.9% |
| Q2 2022 | $4,614,000 | +8.0% | 429,630 | -4.8% | 0.04% | +25.0% |
| Q1 2022 | $4,274,000 | -17.1% | 451,358 | +1.1% | 0.03% | -15.2% |
| Q4 2021 | $5,157,000 | +21.4% | 446,459 | +0.4% | 0.03% | +13.8% |
| Q3 2021 | $4,249,000 | -2.7% | 444,893 | -1.8% | 0.03% | 0.0% |
| Q2 2021 | $4,368,000 | +44.9% | 453,155 | +48.5% | 0.03% | +45.0% |
| Q1 2021 | $3,015,000 | -24.9% | 305,175 | +75.5% | 0.02% | -31.0% |
| Q4 2020 | $4,016,000 | +41.0% | 173,922 | -13.8% | 0.03% | +20.8% |
| Q3 2020 | $2,848,000 | -8.0% | 201,676 | -1.8% | 0.02% | -11.1% |
| Q2 2020 | $3,096,000 | – | 205,295 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |